Syndax Pharmaceuticals 2025 年第三季度收益预览

* Syndax Pharmaceuticals (SNDX [https://seekingalpha.com/symbol/SNDX]) 计划于 11 月 3 日星期一收盘后公布第三季度盈利结果。
共识 EPS 预估为 -0.71 美元 [https://seekingalpha.com/symbol/SNDX/earnings/estimates]（+27.6% Y/Y），共识收入预估为 4797 万美元（+283.8% Y/Y）。在过去 3 个月中，EPS 预估出现了 10 次上调 [https://seekingalpha.com/symbol/SNDX/earnings/revisions] 和0向下。收入预测有 10 次向上修正，0 次向下修正。

有关 SYNDAX 制药的更多信息

* Syndax 扩大 Revuforj 批准，购买 [https://seekingalpha.com/article/4833527-syndax-expands-revuforj-approval]
* Syndax Pharmaceuticals, Inc. (SNDX) 讨论 FDA 批准 Revuforj 治疗复发或难治性 NPM1 突变急性髓系白血病转录本[https://seekingalpha.com/article/4833320-syndax-pharmaceuticals-inc-sndx-discusses-fda-approval-of-revuforj-for-relapsed-or-refractory]
* Syndax Pharmaceuticals, Inc. (SNDX) 讨论 FDA 批准 Revuforj 治疗复发或难治性 NPM1 突变急性髓性白血病 - 幻灯片[https://seekingalpha.com/article/4833321-syndax-pharmaceuticals-inc-sndx-discusses-fda-approval-of-revuforj-for-relapsed-or-refractory]
* Syndax 获得 Revuforj 治疗急性髓性白血病的额外适应症 [https://seekingalpha.com/news/4508347-syndax-gains-additional-indicate-revuforj-acute-myeloid-leukemia]
* Syndax 恢复在 Stifel 购买新推出的药物 [https://seekingalpha.com/news/4493767-syndax-stock-resumed-buy-stifel]